comparemela.com
2
3
4
5
6
7
8
Latest Breaking News On - Tina cascone - Page 1 : comparemela.com
Perioperative Nivolumab Regimen Improves EFS, Resection Rates in Stage III N2/non-N2 NSCLC
Neoadjuvant nivolumab/chemotherapy, followed by surgery and adjuvant nivolumab, significantly improved EFS in stage III N2 and stage III non-N2 NSCLC.
Texas
United-states
America
American
Bristol-myers-squibb
Tina-cascone
University-of-texas-md-anderson-cancer-center
Boehringer-ingelheim
Mark-foundation-for-cancer-research
American-joint-committee-on-cancer
Astrazeneca
Serono
Opdivo Before and After Surgery Improves Event-Free Survival in NSCLC
Some patients with stage 3 non-small cell lung cancer saw benefits from Opdivo plus chemotherapy followed by surgery then Opdivo, researchers found.
Houston
Texas
United-states
Tina-cascone
University-of-texas-md-anderson-cancer-center
Drug-administration
Cancer-center
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
United-states
Japan
South-korea
Taiwan
American
Pushkar-mutha
Mariat-bourlon
Tycel-jovelle-phillips
Tony-mok
Lin-wang
Peter-robert-galle
Charlene-mantia
Perioperative Nivolumab Tops Chemo for Survival in Resectable Lung Cancer
Researchers found that the percentage of patients with 18-month event-free survival was 70.2% and 50% in the nivolumab and chemotherapy groups.
Houston
Texas
United-states
Tina-cascone
Bristol-myers-squibb
University-of-texas-md-anderson-cancer-center
Healthday-news
New-england-journal
Cancer-center
Perioperative Nivolumab Tops Chemo for Survival in Resectable Lung Cancer
Significantly more patients had 18-month event-free survival in nivolumab versus chemotherapy group.
Houston
Texas
United-states
Tina-cascone
University-of-texas-md-anderson-cancer-center
Bristol-myers-squibb
Healthday-news
New-england-journal
Cancer-center
vimarsana © 2020. All Rights Reserved.